Hepatocellular carcinoma · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic HCV infection†‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Health‐related quality of life · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver transplantation · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Decompensated liver disease · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cirrhosis · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Serious adverse events · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes serious adverse events compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Quality of life · people with hepatosplenic schistosomiasis
1 finding from 1 review
Rebleeding · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes variceal rebleeding rate compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Encephalopathy · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes encephalopathy compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Ascites · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes ascites compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Any re‐intervention · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes any re‐intervention compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review